UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB
(Mark  One)
[X]  QUARTERLY  REPORT  UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF  1934   For  the  quarterly  period  ended  November 30, 2002
                                                        -----------------
[ ]  TRANSITION  REPORT  UNDER  SECTION  13  OR  15(d)  OF  THE  EXCHANGE  ACT
     For  the  transition  period  from __________ to _____________

     Commission file number 000-31567

                                VITATONICS CORP.
                                -----------------
        (Exact name of small business issuer as specified in its charter)

NEVADA                                                  35-0511303
------                                                  ------------
(State or other jurisdiction                           (I.R.S. Employer
of incorporation or organization)                      Identification No.)


                   38 THORN OAK, DOVE CANYON, CALIFORNIA 92679
                   -------------------------------------------
                    (Address of principal executive offices)

                                  949.589.8912
                                 --------------
                           (Issuer's telephone number)

Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing Requirements for the past 90 days.  Yes  [X ]   No  [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: 28,546,972 common shares issued and
outstanding, as of November 30, 2002

Transitional  Small  Business  Disclosure  Format  (Check one):
      Yes [ ]     No [X]


                                       1
<PAGE>


                          PART I- FINANCIAL INFORMATION


ITEM  1.     FINANCIAL  STATEMENTS.




                                VITATONICS CORP.
                          (A Development Stage Company)

                              FINANCIAL STATEMENTS

                     November 30, 2002 and February 28, 2002






                                       2
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                                 Balance Sheets




<TABLE>
<CAPTION>
                                     ASSETS
                                     ------
<S>                                   <C>                                 <C>                   <C>
                                                                      November 30,          February 28,
                                                                          2002                 2002
                                                                   -----------------     -----------------
                                                                       (Unaudited)

CURRENT ASSETS

   Cash                                                            $               -     $               -
                                                                   ----------------      -----------------

     Total Current Assets                                                          -                     -
                                                                   -----------------     -----------------

     TOTAL ASSETS                                                  $               -     $               -
                                                                   =================     =================


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
                 ----------------------------------------------

CURRENT LIABILITIES

   Accounts payable                                                $          12,532     $          11,493
   Accounts payable - related parties                                         38,794                32,841
   Accrued expenses                                                              100                   100
   Accrued interest                                                           14,608                13,258
   Notes payable - related parties                                            45,000                45,000
                                                                   -----------------     -----------------

     Total Current Liabilities                                               111,034               102,692
                                                                   -----------------     -----------------

     Total Liabilities                                                       111,034               102,692
                                                                   -----------------     -----------------

STOCKHOLDERS' EQUITY (DEFICIT)

   Common stock, par value $0.001; authorized
     50,000,000 shares; 28,546,972 shares issued
     and outstanding                                                          28,547                28,547
   Additional paid-in capital                                                767,104               767,104
   Deficit accumulated prior to the development stage                       (989,057)             (989,057)
   Retained earnings during the development stage                             82,372                90,714
                                                                   -----------------     -----------------

     Total Stockholders' Equity (Deficit)                                   (111,034)             (102,692)
                                                                   -----------------     -----------------

     TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY (DEFICIT)                                             $               -     $               -
                                                                   =================     =================
</TABLE>



The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                                        From
                                                                                                      Inception
                                                                                                       Of the
                                                                                                     Development
                                                                                                      Stage on
                               For the Three Months Ended           For the Nine Months Ended         March 1,
                                      November 30,                        November 30,              2001 through
                           ----------------------------------  ---------------------------------    November 30,
                                  2002             2001              2002             2001              2002
                           ----------------  ----------------  ---------------   ---------------  ----------------
<S>                               <C>              <C>               <C>               <C>              <C>

REVENUES                   $              -  $              -  $             -   $             -  $              -
                           ----------------  ----------------  ---------------   ---------------  ----------------
EXPENSES
   General and
    administrative                    1,233            18,675            5,610            25,638            34,563
                           ----------------  ----------------  ---------------   ---------------  ----------------
     Total Expenses                   1,233            18,675            5,610            25,638            34,563
                           ----------------  ----------------  ---------------   ---------------  ----------------
LOSS FROM
 OPERATIONS                          (1,233)          (18,675)          (5,610)          (25,638)          (34,563)
                           ----------------  ----------------  ---------------   ---------------  ----------------
OTHER (EXPENSE)

   Interest expense                  (1,832)           (2,698)          (2,732)           (8,096)          (11,278)
                           ----------------  ----------------  ---------------   ---------------  ----------------

     Total Other
      (Expense)                      (1,832)           (2,698)          (2,732)           (8,096)          (11,278)
                           ----------------  ----------------  ---------------   ---------------  ----------------
LOSS BEFORE
 INCOME TAXES AND
 EXTRAORDINARY
 ITEM                                (3,065)          (21,373)          (8,342)          (33,734)          (45,841)

   Income taxes                           -                 -                -                 -                 -
                           ----------------  ----------------  ---------------   ---------------  ----------------
LOSS BEFORE
 EXTRAORDINARY
 ITEM                                (3,065)          (21,373)          (8,342)          (33,734)          (45,841)
                           ----------------  ----------------  ---------------   ---------------  ----------------
   Gain on
    extinguishments
    of debt                               -            57,903                -            57,903           128,213
                           ----------------  ----------------  ---------------   ---------------  ----------------
NET INCOME (LOSS)          $         (3,065) $         36,530  $        (8,342)  $        24,169  $         82,372
                           ================  ================  ===============   ===============  ================
BASIC INCOME (LOSS)
 PER COMMON SHARE:

   Loss before extraordinary
    Item                   $          (0.00) $          (0.00) $         (0.00)  $         (0.00)
                           ================  ================  ===============   ===============
   Extraordinary item      $          (0.00) $           0.00  $         (0.00)  $          0.00
                           ================  ================  ===============   ===============
   Net income (loss)       $          (0.00) $           0.00  $         (0.00)  $          0.00
                           ================  ================  ===============   ===============
WEIGHTED AVERAGE
 NUMBER OF SHARES
 OUTSTANDING                     28,546,972         9,896,972       28,546,972         9,896,972
                           ================  ================  ===============   ===============
</TABLE>





The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                  Statements of Stockholders' Equity (Deficit)

<TABLE>
<CAPTION>
                                                           Common                    Additional
                                             ---------------------------------        Paid-in         Accumulated
                                                  Shares            Amount            Capital           Deficit
                                             ----------------  ---------------   ----------------  ----------------
<S>                                                <C>               <C>                <C>               <C>
Balance, February 28, 1999                          9,896,972  $         9,897   $        550,819  $      (952,519)

Net loss for the year ended
 February 29, 2000                                          -                -                  -          (22,079)
                                             ----------------  ---------------   ----------------  ---------------

Balance, February 29, 2000                          9,896,972            9,897            550,819         (974,598)

Capital contributed for expenses                            -                -              3,294                -

Net loss for the year ended
 February 28, 2001                                          -                -                  -          (14,459)
                                             ----------------  ---------------   ----------------  ---------------

Balance, February 28, 2001                          9,896,972            9,897            554,113         (989,057)

Common stock issued in lieu of
 debt at $0.123 per share                           1,750,000            1,750            212,991                -

Common stock issued in lieu of
 debt at $0.001 per share                           1,000,000            1,000                  -                -

Common stock issued for services
 at $0.001 per share                               15,900,000           15,900                  -                -

Net income for the year ended
 February 28, 2002                                          -                -                  -           90,714
                                             ----------------  ---------------   ----------------  ---------------
Balance, February 28, 2002                         28,546,972           28,547            767,104         (898,343)

Net loss for the nine months ended
 November 30, 2002 (unaudited)                              -                -                  -           (8,342)
                                             ----------------  ---------------   ----------------  ---------------

Balance, November 30, 2002 (unaudited)             28,546,972  $        28,547   $        767,104  $      (906,685)
                                            =================  ===============   ================  ===============

Deficit accumulated prior to the development stage                                                 $      (989,057)
Retained earnings during the development stage                                                              82,372
                                                                                                   ---------------

                                                                                                   $      (906,685)
                                                                                                   ===============
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                            Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                         From
                                                                                                       Inception
                                                                                                        Of the
                                                                                                      Development
                                                                                                       Stage on
                                                                    For the Nine Months Ended          March 1,
                                                                          November 30,               2001 through
                                                               ---------------------------------     November 30,
                                                                     2002             2001                2002
                                                               ---------------   ---------------  ------------------
<S>                                                                  <C>              <C>                 <C>

CASH FLOWS FROM OPERATING ACTIVITIES

   Net income (loss)                                           $        (8,342)  $        24,169  $           82,372
   Adjustments to reconcile loss from operations
    to net cash used by operating activities:
     Extraordinary gain                                                      -           (57,903)           (128,213)
     Common stock issued for services                                        -                  -             15,900
   Changes in assets and liabilities:
     Increase in accrued interest                                        1,350             8,097               9,897
     Increase in accounts payable and
      accounts payable - related party                                   6,992             9,637              19,944
     Increase in accrued expenses                                            -            16,000                 100
                                                               ---------------   ---------------  ------------------

       Net Cash Used by Operating Activities                                 -                 -                   -
                                                               ---------------   ---------------  ------------------

CASH FLOWS FROM INVESTING ACTIVITIES                                         -                 -                   -
                                                               ---------------   ---------------  ------------------

CASH FLOWS FROM FINANCING ACTIVITIES                                         -                 -                   -
                                                               ---------------   ---------------  ------------------

NET DECREASE  IN CASH                                                        -                 -                   -

CASH AT BEGINNING OF PERIOD                                                  -                 -                   -
                                                               ---------------   ---------------  ------------------

CASH AT END OF PERIOD                                          $             -   $             -  $                -
                                                               ===============   ===============  ==================

SUPPLEMENTAL CASH FLOW INFORMATION:

   Cash paid for:

     Interest                                                  $             -   $             -  $                -
     Income taxes                                              $             -   $             -  $                -

NON-CASH FINANCING AND INVESTING ACTIVITIES:

     Common stock issued in lieu of debt                       $             -   $             -  $          215,741
     Common stock issued for services                          $             -   $             -  $           15,900
</TABLE>



The accompanying notes are an integral part of these financial statements.

                                       6
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                        Notes to the Financial Statements
                     November 30, 2002 and February 28, 2002



NOTE 1 -     BASIS OF FINANCIAL STATEMENT PRESENTATION

             The accompanying unaudited condensed financial statements have been
             prepared by the Company pursuant to the rules and regulations of
             the Securities and Exchange Commission. Certain information and
             footnote disclosures normally included in financial statements
             prepared in accordance with accounting principles generally
             accepted in the United States of America have been condensed or
             omitted in accordance with such rules and regulations. The
             information furnished in the interim condensed financial statements
             include normal recurring adjustments and reflects all adjustments,
             which, in the opinion of management, are necessary for a fair
             presentation of such financial statements. Although management
             believes the disclosures and information presented are adequate to
             make the information not misleading, it is suggested that these
             interim condensed financial statements be read in conjunction with
             the Company's most recent audited financial statements and notes
             thereto included in its February 28, 2002 Annual Report on Form
             10-KSB. Operating results for the three and nine months ended
             November 30, 2002 are not necessarily indicative of the results
             that might be expected for the year ending February 28, 2003.

NOTE 2 -      GOING CONCERN

              The Company's financial statements are prepared using generally
              accepted accounting principles applicable to a going concern which
              contemplates the realization of assets and liquidation of
              liabilities in the normal course of business. The Company has not
              yet established an ongoing source of revenues sufficient to cover
              its operating costs and allow it to continue as a going concern.
              The ability of the Company to continue as a going concern is
              dependent on the Company obtaining adequate capital to fund
              operating losses until it becomes profitable. If the Company is
              unable to obtain adequate capital, it could be forced to cease
              operations.

              In order to continue as a going concern, develop a reliable source
              of revenues, and achieve a profitable level of operations the
              Company will need, among other things, additional capital
              resources. A related party will continue to loan the Company
              necessary operating expenses. However, management cannot provide
              any assurances that the Company will be successful in
              accomplishing any of its plans.

              The ability of the Company to continue as a going concern is
              dependent upon its ability to eventually secure other sources of
              financing and attain profitable operations. The accompanying
              financial statements do not include any adjustments that might be
              necessary if the Company is unable to continue as a going concern.

NOTE 3 - RELATED PARTY TRANSACTIONS

              During the nine months ended November 30, 2002, two related
              parties paid $4,900 of the Company's accounts payable. The Company
              has imputed interest at 4% per annum on the balance to related
              parties outstanding longer than one year. At November 30, 2002,
              the Company owed related parties a total of $38,794, which
              includes interest of $1,053. This total amount is included in
              accounts payable - related parties.



                                       7
<PAGE>



                                VITATONICS CORP.
                          (A Development Stage Company)
                        Notes to the Financial Statements
                     November 30, 2002 and February 28, 2002



ITEM  2.     PLAN  OF  OPERATION.


Development of the Company. Our corporate history contains several mergers and
reincorporations. We were originally organized under the laws of the State of
Nevada on June 18, 1990 using the name CCC-Huntor Associates, Inc. and
reincorporated in Texas using the name Aster Buzbuilders, Inc. in June 1995.
Under a Plan of Reorganization and Merger dated May 14, 1996, Aster Buzbuilders,
Inc. was organized for the transaction of any and all lawful business for which
corporations may be incorporated under the Texas Business Corporation Act. It
attempted to establish an Internet-based business by compiling a computer data
base for sellers of small private businesses which would allow Internet access
to such information by potential buyers. The company was not successful in
establishing this business and acquired all the capital stock of Vitatonics
Corp., a Nevada corporation which had been incorporated on February 21, 1995
using the name Fitonics Corporation and which had changed its name to Vitatonics
Corp. on March 10, 1995. Under the Plan of Reorganization and Merger, Vitatonics
Corp. became a wholly-owned subsidiary of Aster Buzbuilders, Inc. which, in
turn, issued 6,000,000 shares of its common stock to the shareholders of
Vitatonics Corp., which then dissolved. This reorganization was accounted for as
a recapitalization of Vitatonics Corp. for accounting purposes because its
shareholders controlled the company after the merger. Our sales and executive
offices are located at 38 Thorn Oak, Dove Canyon, California 92679 in our
president's residence. Our telephone number is (949)589.8912. Our financial
administrative offices were originally in Vancouver, Canada because our
co-founder, Sam Kalenuik, lived there. This administrative office was moved to
23456 South Pointe Drive, Lake Forest, California, our chief financial officer's
residence, in July, 1997, then to our president's residence in December, 1997.

We were in the vitamin business but we currently have minimal operations.
Beginning in March, 1995 and continuing through approximately December, 1997 we
were engaged in the manufacturing, packaging and sale and distribution of
vitamins, minerals and nutritional supplements. We had developed our own
products and, during that period, we also distributed vitamin, mineral and
nutritional supplement brands of other producers. Daniel McCormick was a
co-founder, with Sam Kalenuik, of our vitamin business. Mr. McCormick had
extensive experience distributing vitamin and health products with Herbalife
from 1981 through 1992 and with BodyWise from 1990 through 1995. Mr. McCormick
remains as an officer and director of the company, but Mr. Kalenuik decided to
pursue other business ventures in the web-page building business in 1997. When
Mr. Kalenuik decided to resign from his positions with the company in 1997, he
agreed that we could cancel the restricted stock that he owned. That stock was
not canceled until 1999.



                                       8
<PAGE>


In December 1997, we ceased our production and packaging of vitamin products.

From December, 1997 through November, 1998, we generated some revenues from the
sale of our existing inventory. Other than selling our inventory, we have been
essentially inactive since December, 1997. When the existing inventory was sold
we discontinued any sales operations. Our subsequent activity has been the
continued development, by Mr. McCormick at his own expense, of potential new
products while we have sought a merger or joint venture partner or other source
of financing, such as the sale of our private equity or a loan from a private
party. Our Chief Financial Officer, George Farquhar, is a business consultant to
public and private companies and has been actively searching for a merger or
joint venture partner by informing his business contacts, including Vitatonics'
attorneys and public accountants, that Vitatonics is open to a merger or joint
venture with an operating company, subject to required Board of Directors and
shareholder approval.

We have an accumulated deficit of $906,685 at November 30, 2002, and we expect
that deficit to continue to increase as we incur legal and accounting expenses
incidental to our reporting obligations as a public company. Our accountants
have expressed concern that we will not be able to continue as a going concern
because of our continuing losses. While we have net operating loss carryforwards
of approximately $1,000,000 that may be offset against future taxable income
through 2021, these loss carryforwards will not do us any good unless we can
generate income. We are currently classified as a "dormant enterprise" for
accounting purposes because we are inactive and are not carrying on development
stage activities.

If we are able to attract a merger or joint venture partner, or obtain
sufficient financing, our present plan of operation for the next twelve months
is to develop, and possibly reintroduce updated versions of, our own brands of
vitamins and nutritional supplements. However, because we have no funds
available, we are not currently spending any funds on research and development
of these new products, nor have we spent any funds on research and development
during the last two years. However, Mr. McCormick has continued to revise and
develop a proposed product line based on the sales trends in the industry.
Because of Mr. McCormick's significant experience, we believe that, if we can
obtain sufficient working capital and research and development funds, we could
design, produce and distribute a successful product line.

Should we raise sufficient funds to re-introduce our vitamin product line and
develop new product lines, we plan to market our vitamin products to health food
stores and other wholesale and resale sources. We also hope to acquire the right
to sell or distribute other parties' vitamin products. We also plan to
re-establish our past marketing network and add additional products as
opportunity allows, either through licensing the products of others or through
corporate acquisitions.

Results of Operations: Our operations during the quarter ended November 30,
2002, have been minimal, and consisted of the preparation of financial
statements and this quarterly report. We did not generate any revenues. Our
total expenses for the three months ended November 30, 2002 were $1,233,
consisting of general, administrative, and accounting expenses, compared to
$18,675 during the same three month period in 2001 (during that time we were
spending more on legal and accounting costs relating to becoming current in our
reporting obligations). During the three months ended November 30, 2002 we also
incurred $1,832 in interest expense, for a combined net loss for the period of
$3,065. We have no funds presently available for research and development
activities and have not spent any funds on research and development activities
in the last year.

                                       9
<PAGE>

During the nine months ended November 30, 2002, two related parties paid $4,900
of our accounts payable. We have imputed interest at 4% per annum on the balance
to related parties outstanding longer than one year. At November 30, 2002, we
owed related parties a total of $38,794, which includes interest of $1,053.

Substantial Doubt About Our Viability as a Going Concern. We have incurred
significant losses which raises substantial doubt about our ability to continue
as a going concern. As discussed above, we are considering a merger or joint
venture with an operating company as one method of addressing this problem. We
continue to incur costs for professional services and interest continues to
accrue on our outstanding promissory notes. Our current liabilities at November
30, 2002 were $111,034. Because of these ongoing expenses, which are
approximately $25,000 annually, we will not become profitable until we reach an
annual sales volume of at least $250,000. We typically sell our products at six
times cost, incurring sales commissions of one half the sales price. To achieve
sales of $250,000 annually, we anticipate operating expenses, overhead and
employee costs of approximately $5,000 per month.

Liquidity and Capital Resources. We currently have no cash available and will
need to raise additional funds to continue satisfying our reporting obligations
and to re-introduce our vitamin product line and develop new product lines. We
are currently inactive and are classified as a "dormant enterprise" because we
are not currently undertaking development stage activities. Because we are not
generating any revenues from the sale or licensing of our products, our only
external source of liquidity is the sale of our capital stock.

We Do Not Have Any Employees. We do not currently have any employees because we
are using consultants and subcontractors to promote our business and for
accounting and legal services on an as-needed basis. Until we can raise
sufficient funds to develop our own product lines, we plan to negotiate
licensing agreements for products developed by other companies. If we were able
to enter into any licensing agreements, we would distribute those licensed
products and receive income similar to a sales commission on all products
distributed by us. At such time as we have developed our own product lines, we
anticipate negotiating and entering into and manufacturing and production
subcontracts with existing manufacturing and production facilities to
manufacture our products so that we will require very few employees, if any,
during the next 12 months.



                                       10
<PAGE>


                           PART II - OTHER INFORMATION

ITEM  1.     LEGAL  PROCEEDINGS.

We know of no material, active or pending legal proceedings against us, nor are
we involved as a plaintiff in any material proceedings or pending litigation.
There are no proceedings in which any of our directors, officers or affiliates,
or any registered or beneficial shareholder, is an adverse party or has a
material interest adverse to our interest.

ITEM  2.     CHANGES  IN  SECURITIES.

We did not issue any securities during the three month period ended November 30,
2002.

ITEM  3.     DEFAULTS  UPON  SENIOR  SECURITIES.

None.

ITEM  4.     SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS.

None.

ITEM  5.     OTHER  INFORMATION.

None.

ITEM  6.     EXHIBITS  AND  REPORTS  ON  FORM  8-K.

Reports  on  Form  8-K

We did not file any reports on Form 8-K during the quarter ended November 30,
2002.

Exhibits  Required  by  Item  601  of  Regulation  S-B


Index to Exhibits        Description of Exhibits                 Page
-----------------        -----------------------                 ----

2.1                           Plan of Reorganization               *

3.1                           Articles of Incorporation            *
                              Fitonics Corporation


                                       11
<PAGE>


3.2                           Certificate of Amendment to          *
                              Articles of Incorporation
                              (March 10, 1995)

3..3                          By-Laws of Vitatonics Corp.          *

3.4                           Certificate of Amendment to
                              Articles of Incorporation
                              (May 13, 1996)                       **

4.                            Instruments Defining Rights
                              of Security Holders (not applicable)

10.                           Material Contracts (not applicable)

11.                           Statement re: Computation of Per
                              Share Earnings (see financial statements
                              incorporated herein)

15.                           Not applicable

18.                           Not applicable

19.                           Not applicable

22.                           Not applicable

23.                           Not applicable

24.                           Power of Attorney (not applicable)

*  Previously filed with the Securities and Exchange Commission on September 19,
2000 as an exhibit to the company's Registration Statement on Form 10-SB.

** Previously filed with the Securities and Exchange Commission on February 12,
2001 as an exhibit to the company's Amendment No. 1 to Registration Statement on
Form 10-SB.


                                       12
<PAGE>


                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


VITATONICS CORP.

     By:       /s/  George Farquhar
               Secretary/Chief Financial Officer
     Date:     January 13, 2003






                                       13
<PAGE>



CERTIFICATIONS
--------------

I, Daniel McCormick, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Vitatonics Corp.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         a) all significant deficiencies in the design or operation of internal
         controls which could adversely affect the registrant's ability to
         record, process, summarize and report financial data and have
         identified for the registrant's auditors any material weaknesses in
         internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: January 13, 2003


/s/ Daniel McCormick
----------------------
Daniel McCormick
Chief Executive Officer



                                       14
<PAGE>


CERTIFICATIONS
--------------

I, George Farquhar, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Vitatonics Corp.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         a) all significant deficiencies in the design or operation of internal
         controls which could adversely affect the registrant's ability to
         record, process, summarize and report financial data and have
         identified for the registrant's auditors any material weaknesses in
         internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: January 13, 2003

/s/ George Farquhar
----------------------
George Farquhar
Chief Financial Officer